TLX
HEALTHCARETelix Pharmaceuticals Ltd
$11.11+0.07 (+0.63%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving TLX Today?
No stock-specific AI insight has been generated for TLX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.28$18.49
$11.11
Fundamentals
Market Cap$3.8B
P/E Ratio—
EPS$-0.02
Dividend Yield—
Dividend / Share—
ROE-0.0%
Profit Margin-0.0%
Debt / Equity—
Trading
Volume88K
Avg Volume (10D)—
Shares Outstanding338.8M
TLX News
24 articles- New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCCYahoo Finance·May 4, 2026
- Insider Buying: Telix Pharmaceuticals Co-Founder Bought US$997k Of SharesYahoo Finance·May 1, 2026
- TLX101-Px (Pixlumi®) MAA Accepted in EuropeYahoo Finance·May 1, 2026
- How TLX597-Tx Phase 2 Dosimetry Data Will Impact Telix Pharmaceuticals (ASX:TLX) InvestorsYahoo Finance·Apr 30, 2026
- Telix Pharmaceuticals Webinar Highlights Next-Gen PSMA Therapy, OPTIMAL-PSMA Enrollment Nears EndMarketbeat·Apr 30, 2026
- OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate CancerGlobeNewswire Inc.·Apr 29, 2026
- Regeneron Stock Tumbles on Earnings. Upcoming Data Matter More for the Stock.Yahoo Finance·Apr 29, 2026
- Telix Pharmaceuticals (TLX): How Are Its Clinical Programs Doing?Yahoo Finance·Apr 28, 2026
- Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio ApproachGlobeNewswire Inc.·Apr 27, 2026
- ASX Growth Leaders With High Insider Ownership April 2026Yahoo Finance·Apr 26, 2026
- Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™Yahoo Finance·Apr 23, 2026
- ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026Yahoo Finance·Apr 21, 2026
- Regeneron Broadens Dupixent Use And Enters Radiopharmaceuticals With TelixYahoo Finance·Apr 20, 2026
- Regeneron Pharmaceuticals (REGN) Announces Collaboration With Telix Pharmaceuticals LimitedYahoo Finance·Apr 20, 2026
- Telix Pharmaceuticals (TLX) Doses First Patient in Phase 3 Trial for Brain Cancer TherapyYahoo Finance·Apr 19, 2026
- Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent GlioblastomaYahoo Finance·Apr 14, 2026
- Telix Successfully Prices and Upsizes US$600 Million Convertible BondsYahoo Finance·Apr 14, 2026
- A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Recent Share Price MovesYahoo Finance·Apr 14, 2026
- Telix Expands Board As Valuation And Momentum Draw Investor AttentionYahoo Finance·Apr 14, 2026
- Regeneron Boosts Cancer Pipeline Through Telix CollaborationYahoo Finance·Apr 14, 2026
- FDA Accepts NDA for TLX101-Px (Pixclara®)GlobeNewswire Inc.·Apr 9, 2026
- Telix Strengthens Board with Additional Director AppointmentsGlobeNewswire Inc.·Apr 8, 2026
- Q1 2026: Strong Revenue Growth and Therapeutics Pipeline AdvancementGlobeNewswire Inc.·Apr 6, 2026
- Telix Appoints David Gill as Non-Executive DirectorGlobeNewswire Inc.·Apr 1, 2026
All 24 articles loaded
Price Data
Open$11.00
Previous Close$11.04
Day High$11.15
Day Low$10.90
52 Week High$18.49
52 Week Low$6.28
52-Week Range
$6.28$18.49
$11.11
Fundamentals
Market Cap$3.8B
P/E Ratio—
EPS$-0.02
Dividend Yield—
Dividend / Share—
ROE-0.0%
Profit Margin-0.0%
Debt / Equity—
Trading
Volume88K
Avg Volume (10D)—
Shares Outstanding338.8M
About Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company is headquartered in North Melbourne, Australia.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—